Sequoia China Leads USD150m Series B for Chinese Biotech Visen Pharmaceuticals

Sequoia Capital China led a USD150m Series B for China-based biotech firm Visen Pharmaceuticals, with participation from OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital, and CDG Capital, as well as follow-on from existing investors, including Ascendis Pharma A/S, Vivo Capital, and… Read More

IDB Commits Combined USD30m to Vinci and HMC Funds

IDB Invest has agreed to commit a combined USD30m to funds managed by Vinci Partners and HMC Capital. IDB agreed to invest up to USD10m in Vinci Impact and Return Fund IV, a fund targeting investments in SMEs across the education, health care, IT, and environmentally friendly consumer… Read More

OP Finnfund Global Impact Fund I Reaches USD166m Second Close

OP Finnfund Global Impact Fund I has reached a EUR135m (approximately USD166m) second close. The impact vehicle, which targets investments in emerging markets across renewable energy, financial institutions, and sustainable agriculture, reached a EUR76m (~USD93.5m) first close in June 2020. The second round of funding ended in December… Read More



(default archive template)